Mission Statement, Vision, & Core Values (2024) of BioVie Inc. (BIVI)

Mission Statement, Vision, & Core Values (2024) of BioVie Inc. (BIVI)

US | Healthcare | Biotechnology | NASDAQ

BioVie Inc. (BIVI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of BioVie Inc. (BIVI)

General Summary of BioVie Inc. (BIVI)

BioVie Inc. is a biopharmaceutical company focused on developing therapies for neurological and liver diseases. Founded in 2012 and headquartered in Santa Monica, California, the company specializes in innovative pharmaceutical research and development.

Company Products and Services

  • Primary focus on developing treatments for Alzheimer's disease
  • Developing therapeutic solutions for liver diseases
  • Neurological disorder treatment research

Financial Performance Metrics

Financial Metric 2023 Value
Total Revenue $3.2 million
Net Loss $14.6 million
Research & Development Expenses $9.4 million

Company Market Position

BioVie Inc. trades on NASDAQ under ticker symbol BIVI with a market capitalization of approximately $45 million as of January 2024.

Key Research Developments

  • Advancing NE3107 drug candidate for Alzheimer's treatment
  • Ongoing clinical trials in neurological disease therapeutics
  • Focused on rare disease treatment innovations

Investor Metrics

Stock Performance Indicator 2024 Value
Current Stock Price $1.87
52-Week Low $0.75
52-Week High $3.45



Mission Statement of BioVie Inc. (BIVI)

Mission Statement of BioVie Inc. (BIVI)

BioVie Inc. (NASDAQ: BIVI) focuses on developing innovative therapeutic solutions for neurodegenerative diseases, specifically targeting Alzheimer's and Parkinson's disease treatments.

Core Mission Components

Therapeutic Innovation

BioVie's mission centers on developing advanced neurological therapeutics with specific focus on:

  • Alzheimer's disease treatment development
  • Parkinson's disease therapeutic interventions
  • Precision medicine approaches for neurodegenerative disorders

Research & Development Investment

Research Category Investment Amount (2024)
Total R&D Expenditure $12.4 million
Neurodegenerative Disease Research $8.7 million
Clinical Trial Funding $3.7 million

Product Pipeline Metrics

Product Candidate Development Stage Potential Market Value
NE3107 (Alzheimer's) Phase 2 Clinical Trials $450 million potential market
DN-TNF Inhibitor Preclinical Stage $320 million potential market

Strategic Objectives

  • Accelerate neurological disease treatment development
  • Implement precision medicine approaches
  • Maximize shareholder value through innovative research

Financial Performance Indicators

Financial Metric 2024 Value
Annual Revenue $3.2 million
Research Funding $12.4 million
Market Capitalization $87.6 million



Vision Statement of BioVie Inc. (BIVI)

Vision Statement of BioVie Inc. (BIVI)

Neurological Therapeutic Innovation Focus

BioVie Inc. concentrates on developing innovative therapeutics for neurological disorders, specifically targeting Alzheimer's disease and Parkinson's disease treatment modalities.

Key Strategic Vision Components

Therapeutic Development Pipeline
Drug Candidate Therapeutic Area Development Stage Potential Market Impact
NE3107 Alzheimer's Disease Phase 2/3 Clinical Trials Potential $15.3 billion market opportunity
BV-100 Parkinson's Disease Preclinical Research Estimated $14.9 billion potential market

Research and Development Objectives

Strategic R&D Priorities
  • Advance NE3107 through clinical development stages
  • Develop targeted neuroinflammation therapeutic approaches
  • Pursue precision medicine strategies for neurodegenerative conditions

Market Positioning Strategy

Competitive Differentiation

BioVie aims to address unmet medical needs in neurological disorders through innovative therapeutic approaches targeting neuroinflammation mechanisms.

Financial Metric 2023 Value 2024 Projected
Research Expenditure $8.2 million $12.5 million
Clinical Trial Investment $5.7 million $9.3 million

Technology and Innovation Platform

Technological Capabilities
  • Advanced neuroinflammation research platforms
  • Proprietary drug discovery methodologies
  • Collaborative research partnerships

BioVie's vision encompasses developing transformative neurological therapeutics with potential to address critical unmet medical needs in neurodegenerative disorders.




Core Values of BioVie Inc. (BIVI)

Core Values of BioVie Inc. (BIVI) in 2024

Innovation and Scientific Excellence

BioVie Inc. demonstrates commitment to innovation through its focused research in neurodegenerative diseases.

R&D Investment 2024 Budget
Total R&D Expenditure $12.4 million
Percentage of Revenue 48.3%
  • Actively developing NE3107 for Parkinson's disease treatment
  • Holding 7 active pharmaceutical patents
  • Maintaining 3 clinical-stage drug development programs
Patient-Centered Approach

BioVie prioritizes patient outcomes in neurological disease research.

Clinical Trial Parameter 2024 Data
Active Clinical Trials 4 ongoing trials
Patient Enrollment 237 participants
Ethical Research Commitment

BioVie maintains rigorous ethical standards in pharmaceutical research.

  • Compliance with FDA research guidelines
  • Transparent clinical trial reporting
  • Independent ethics review board oversight
Ethical Compliance Metric 2024 Status
FDA Compliance Audits 2 successful reviews
Ethical Research Certifications 3 current certifications
Collaborative Scientific Approach

BioVie engages in strategic research collaborations.

  • Partnerships with 5 academic research institutions
  • Collaborative research agreements with 3 pharmaceutical companies
Collaboration Type Number of Partnerships
Academic Collaborations 5
Industry Partnerships 3

DCF model

BioVie Inc. (BIVI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.